March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
Oppdag vitenskapen bak CAR T-celleterapibehandling i India! Utforsk hvordan denne revolusjonerende behandlingen forvandler immuncellene dine til kreftbekjempere. Les bloggen vår nå for å lære mer om denne mirakuløse terapien og hvordan ..
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..
Mai 2023: For voksne pasienter med høygradig B-celle lymfom (HGBL), ikke annet spesifisert (NOS), eller diffust stort B-celle lymfom (DLBCL) som ikke tidligere har mottatt behandling og som har en internasjonal prognostisk indeks.
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
November 2022: Kombinasjonen av doksorubicin, vinkristin, etoposid, prednison og cyklofosfamid med brentuximab vedotin (Adcetris, Seagen, Inc.) er godkjent av Food and Drug Administration for bruk hos barn og..